Company profile
DIAMEDICA THERAPEUTICS INC.
NASDAQ:DMACBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| RINVECALINASE ALFA | phase2 | — | 4 | completed, withdrawn |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (7)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01845064 | phase1_2 | completed | 2013-04-01 | 2014-09-01 | DiaMedica Therapeutics Inc | A Study to Evaluate the Safety and Effectiveness of DM199 in Healthy Subjects and Type 2 Diabetes Patients |
| NCT02868996 | phase1 | completed | 2016-09-01 | 2017-03-01 | DiaMedica Therapeutics Inc | An Open Label, Phase 1b, Ascending Dose Study of DM199 |
| NCT06875141 | — | withdrawn | 2025-05-01 | 2025-05-01 | DiaMedica Therapeutics Inc | DM199 for Pregnancy Complications |
| NCT03290560 | phase2 | completed | 2018-01-19 | 2020-01-23 | DiaMedica Therapeutics Inc | Evaluation to Assess Safety and Tolerability of DM199 in Subjects With Acute Ischemic Stroke |
| NCT04123613 | phase2 | completed | 2019-12-17 | 2022-03-16 | DiaMedica Therapeutics Inc | Multiple Doses of DM199 in Patients With Chronic Kidney Disease (REDUX) |
FDA applications (0)
No records yet.